Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
388.33(c) 383.7(c) 387.25(c) 390.28(c) 390.19(c) Last
644 606 610 455 680 642 1 147 805 372 844 Volume
+0.48% -1.19% +0.93% +0.78% -0.02% Change
More quotes
Financials (USD)
Sales 2018 6 441 M
EBIT 2018 2 710 M
Net income 2018 1 857 M
Finance 2018 3 553 M
Yield 2018 -
Sales 2019 7 100 M
EBIT 2019 2 939 M
Net income 2019 2 224 M
Finance 2019 5 737 M
Yield 2019 -
P/E ratio 2018 22,17
P/E ratio 2019 20,93
EV / Sales2018 5,88x
EV / Sales2019 5,03x
Capitalization 41 417 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases.It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP.The company was founded by... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
09/20REGENERON PHARMACEUTICALS : FDA to Review Supplemental Biologics License Applica..
AQ
09/20REGENERON PHARMACEUTICALS : Patent Issued for Stabilized Formulations Containing..
AQ
09/20REGENERON PHARMACEUTICALS : FDA to Review EYLEA aflibercept Injection for the Tr..
AQ
09/19REGENERON PHARMACEUTICALS : Positive phase 3 results presented for dupixent show..
AQ
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/17REGENERON PHARMACEUTICALS : FDA to Review EYLEA Injection for the Treatment of D..
AQ
09/15REGENERON PHARMACEUTICALS : Positive Phase 3 Results Presented for Dupixent® (du..
PR
09/14REGENERON PHARMACEUTICALS : FDA to Review Supplemental Biologics License Applica..
AQ
09/13REGENERON PHARMACEUTICALS : Studies from Regeneron Pharmaceuticals Inc. Describe..
AQ
09/13REGENERON PHARMACEUTICALS : FDA to Review EYLEA (aflibercept) Injection for the ..
PR
More news
Sector news : Bio Therapeutic Drugs
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- 2nd Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
More sector news : Bio Therapeutic Drugs
MarketScreener Strategies on REGENERON PHARMACEUTICALS 
REGENERON PHARMACEUTICALS - 2017
A long term support level to be taken advantage of
BUY
REGENERON PHARMACEUTICALS - 2017
One can take advantage of the trading range to enter new positions
BUY
More Strategies
Latest Tweets
09/24Arthur Hill: Regeneron Holds Break as Volume Picks Up $REGN
3
09/19$REGN  
09/17$REGN $SNY Regeneron and Sanofi's Dupixent shows treatment benefit in adolesc..
1
09/17$ACOR $ARDX $ARQL $AZN $GLPG $INCY $IRWD $MBRX $MOR $NVS $REGN $RHHBY $STAA $.. 
09/15Regeneron and Sanofi's Dupixent shows treatment benefit in adolescents with a.. 
More tweets
Qtime:108
News from SeekingAlpha
09/19Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron 
09/19GameStop's Fundamentals Are Declining - Cramer's Lightning Round (9/18/18) 
09/17YOUR DAILY PHARMA SCOOP : XBiotech Reports Positive Data, AstraZeneca's New Appr.. 
09/15Regeneron and Sanofi's Dupixent shows treatment benefit in adolescents with a.. 
09/15STOCKS TO WATCH : Oracle Looks To Lift Tech Sector 
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 406 $
Spread / Average Target 4,1%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS3.81%41 417
GILEAD SCIENCES5.56%97 887
VERTEX PHARMACEUTICALS21.56%46 021
NEUROCRINE BIOSCIENCES, INC.56.01%10 822
GENMAB2.04%10 170
SAREPTA THERAPEUTICS INC165.26%9 806